Table 1.
Patients characteristics according phenotype
| Characteristic | Phenotype− (N = 80) | Phenotype+ (n = 12) | p value |
|---|---|---|---|
| Female | 33 (41 %) | 8 (66 %) | 0.13 |
| Mean age (SD) | 60.7 (18.8) | 65.1 (12.3) | 0.20 |
| Metastatic status | 0.8 | ||
| 1 site | 61 (76 %) | 10 (83 %) | |
| >1 site | 19 (24 %) | 2 (17 %) | |
| Primary site | 0.4 | ||
| Stomach | 30 (37) | 5 (42) | |
| Small bowel | 33 (41) | 2 (16) | |
| Other | 17 (22) | 5 (42) | |
| KIT/PDGFR status | 0.006 | ||
| KIT mutation | 64 (79 %) | 7 (58 %) | |
| PDGFR | 2 (3 %) | 3 (25 %) | |
| WT | 14 (18 %) | 2 (17 %) | |
| ECOG PS | 0.79 | ||
| 0–1 | 72 (90 %) | 11 (92 %) | |
| 2 | 8 (10 %) | 1 (8 %) | |
| Liver metastasis | 48 (60 %) | 7 (58 %) | 0.91 |
| Surgery of primary | 74 (92 %) | 11 (92 %) | 0.91 |
| Disease free interval | |||
| <24 months | 20 (25 %) | 4 (33 %) | 0.5 |
| >24 months | 60 (75 %) | 8 (67 %) | |
| Mean LDH (SD) | 332.1 (160.8) | 482.4 (429.8) | 0.39 |
| Mean leucocytes (SD) | 7.1 (3) | 8.1 (5.1) | 0.56 |
| Mean albumin (SD) | 40.9 (7.1) | 39.6 (6.1) | 0.62 |
SD standard deviation